{"entity":{"id":"nct07324304","kind":"trial","name":"NWRD06 DNA Plasmid for HCC After Curative Resection.","aka":[],"tldr":"A phase 2 trial of NWRD06 administered by electroporation in hepatocellular carcinoma, run by Newish Technology (Beijing) Co., Ltd., now recruiting.","summary":"NWRD06 DNA Plasmid for HCC After Curative Resection. is a phase 2 interventional study registered as NCT07324304 by Newish Technology (Beijing) Co., Ltd., with 30 participants planned, started 2025-12-08 and due to reach its primary completion in 2028-12-31. Interventions recorded: NWRD06 administered by electroporation.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07324304","url":"https://clinicaltrials.gov/study/NCT07324304"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07324304","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of NWRD06 in Patients With Hepatocellular Carcinoma After Curative Resection.","sponsor":"Newish Technology (Beijing) Co., Ltd.","enrolled":30,"outcomes":[]},"route":"/trials/nct07324304/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}